Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02450708 · ClinicalTrials.gov registry record · NA
Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes
A NA study of Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 511
- Enrollment target
- 10
- Study locations
NCT02450708: Active NA study of Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02450708 is a NA study of Leukemia that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 511 participants, roughly in line with the 485-participant average among 233 other Leukemia trials with a reported enrollment target. The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02450708, a NA study of Leukemia, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 511 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study tests whether adding certain genetic factors to the process of picking a stem cell donor can decrease the chances that the patient's leukemia will come back after bone marrow transplantation. Stem cell donors are "matched" based on genes called human leukocyte antigens (HLA). Currently, donors are selected largely on the basis of HLA gene typing alone. There is published data to show that donors with specific other genes called killer immunoglobulin-like receptors (KIR) may protect AML patients from having their leukemia return after a transplant. In this study, the best HLA matched donors will be tested for the KIR genes. If there is more than 1 donor available, a recommendation will be provided to study doctors as to which donors have potentially favorable KIR genes. The study doctors may or may not choose to use this donor for transplant or not based on his/her own judgment. Transplant care will not change otherwise as a result of this study. This study is being done to demonstrate that AML patients who have donors with specific KIR and HLA genes will have a better outcome following transplant.
Primary Outcome
Demonstration of evidence of leukemia (\>5% blasts in the bone marrow, peripheral blood blasts, or development of extramedullary disease) after initial achievement of either a CR or CRi.
Conditions Studied
Interventions
- GENETIC KIR genotyping
- GENETIC HLA genotyping
Study Locations (10)
Texas
- Baylor University Medical Center - Dallas
- Md Anderson Cancer Center - Houston
Florida
- Moffitt Cancer Center - Tampa
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic Cancer Center - Rochester
New Jersey
- Hackensack University Medical Center Cancer Center - Hackensack
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Duke University Medical Center - Durham
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 511 participants |
| Start Date | 2015-05 |
| Est. Completion | 2026-05 |
| Phase | NA |
What the registry record for NCT02450708 still lists
NCT02450708 is an interventional study that assigns participants to a tested intervention. The registered 511 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 485-participant average among 233 other Leukemia trials with a reported enrollment target.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 2 interventions - of which KIR genotyping is the first listed.
NCT02450708 lists 10 locations in 9 states (Texas, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT02450708 about?
NCT02450708 is a clinical study titled "Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes". This study tests whether adding certain genetic factors to the process of picking a stem cell donor can decrease the chances that the patient's leukemia will come back after bone marrow transplantation. Stem cell donors are "matched" based on genes called human leukocyte antigens (HLA). Currently, ...
What is the current status of trial NCT02450708?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 511 participants. The study started on 2015-05. Estimated completion is 2026-05.
What conditions does trial NCT02450708 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT02450708?
The interventions under investigation include: KIR genotyping (GENETIC), HLA genotyping (GENETIC).
Who is sponsoring clinical trial NCT02450708?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02450708 being conducted?
This trial has 10 study locations across Florida, Massachusetts, Minnesota, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02450708's enrollment target sits among peer trials
511 17th of 233 higher than 217 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia
RECRUITING · NA
-
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
RECRUITING · NA
-
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
-
Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
- NCT05337410 · 512 participants · NA
YES: Innovative Discussion for Engagement, Achievement, and Service
- NCT06096259 · 512 participants · Phase 2
Preventing Injured Knees From osteoArthritis: Severity Outcomes
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia